Biogen Idec, Isis Pharmaceuticals deal
Isis will receive $9.3 million in milestone payments from Biogen Idec under a 2012 deal granting Biogen Idec an exclusive, worldwide option to develop and commercialize ISIS-SMNRx. Isis received two payments totaling $7.3 million triggered by the dosing of the first child in the 12 mg dose cohort in a Phase II trial evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA) and the dosing of the first child in an open-label extension study for children who have completed dosing in Isis' previous studies. Isis received a third payment of $2 million triggered after the first infant received the fourth ISIS-SMNRx dose about six months after the initial three doses were completed in a trial in infants. Isis plans to present top-line data from both trials this quarter, with more detailed results at the American Academy of Neurology meeting in April. Including the $9.3 million, Isis has received more than $45 million in upfront fees, milestones and other payments from Biogen under the deal. ...